DATABASE
Fully Diluted Subscribe

Nasdaq · Biotech stocks database

VOGX — Vogenx Inc

VOGX (Vogenx Inc) stock: $29.13, $432.7M market cap, $0.2M cash, $432.4M EV. Next expected readout: Oct-27. Lead program: Mizagliflozin 5 mg (Postbariatric Hypoglycemia), Phase 2. Data from Fully Diluted's biotech stocks database.

Share price
$29.13
Market cap
$432.7M
Cash
$0.2M
Enterprise value
$432.4M

Balance sheet

Cash$0.2M
Debt$0.0M
Net cash$0.2M
Enterprise value$432.4M
Basic shares14.9M shares
Fully diluted sharesNot disclosed
Fully diluted market capNot disclosed
Cash per share$0.02

Cash figures as of 2026-03-31. Database snapshot: 2026-09-22.

Price history

Loading VOGX daily closes…

Loading price history…

Upcoming catalysts

ExpectedDrugPhaseIndicationMgmt guide
Nov 12 - Dec 24Mizagliflozin 5 mgPhase 2Postbariatric Hypoglycemia

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Get the weekly biotech catalyst rundown.
Cash runways, financings, and trial readouts for all 714 stocks.
Subscribe to Compounding Ego